Company news
Chongqing Taiji Industry (group) Co., Ltd. Class A (SSE:600129) news
Chongqing Taiji Industry (group) Co., Ltd. Class A news releases on 6ix. Latest, Sep 24, 2026: "CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Announcement…
Press releases & updates
"CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Announcement on Progress of Bankruptcy Reorganization of Wholly-owned Subsidiary
September 23, 2026
"CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Chongqing Jurisdiction and Semi-annual Performance Briefing
September 17, 2026
"CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Announcement on Release of Pledge and Pledge of Equity of Controlling Shareholder
August 27, 2026
"CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Semi-annual Report for 2026
August 25, 2026
"CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Announcement on Resolutions of the 40th Meeting of the 10th Board of Directors
August 10, 2026
"CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Announcement on Postponement of the 2nd Extraordinary General Meeting in 2026
July 29, 2026
"CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026
July 20, 2026
"CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Announcement on the Sale of Idle Assets
July 17, 2026
"CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading
July 10, 2026
"CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD."Announcement on Pledge of Equity of Controlling Shareholder
July 1, 2026
"Chongqing Taiji Industry (Group) Co., Ltd."Announcement on Release of Pledge of Equity of Controlling Shareholder
June 30, 2026
Announcement on Obtaining Drug Registration Certificate for Atomoxetine Hydrochloride Capsules
June 10, 2026
Announcement on Participating in the 2025 SSE Main Board Benefit the People & Boost Consumption - Rural Revitalization Collective Online Performance Briefing
June 2, 2026
Announcement on Passing of the Generic Drug Consistency Evaluation for Digoxin Injection
May 22, 2026
Announcement on DSC158A Tablets Obtaining Notice of Approval for Drug Clinical Trials
May 18, 2026
Announcement on Obtaining Drug Registration Certificate for Metformin Hydrochloride and Empagliflozin Tablets (I)
May 13, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 12, 2026
Report for Q1 2026
April 29, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Shuangling Anti-diarrhea Granules
April 13, 2026
Announcement on Release of Pledge and Pledge of Equity of Controlling Shareholder
April 8, 2026
Announcement on Resolutions of the 37th Meeting of the 10th Board of Directors
March 27, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 27, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
February 6, 2026
Announcement on Expected Increase in Performance for 2025
January 30, 2026
Announcement on Resolutions of the 35th Meeting of the 10th Board of Directors
January 22, 2026
Announcement on Change of the Company's Email Address
December 29, 2025
Indicative Announcement on Proposed Absorption and Merger Suspension of Shareholders
December 26, 2025
Announcement on Proposed Public Listing and Transfer of Equity Interest in Joint-stock Company by a Wholly-owned Subsidiary
December 23, 2025
Announcement on Resolutions of the 33rd Meeting of the 10th Board of Directors
December 22, 2025
Announcement on Release of Pledge of Equity of Controlling Shareholder
December 19, 2025
Announcement on Progress in the Bankruptcy Liquidation of Wholly-owned Subsidiary
December 9, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
November 13, 2025
Announcement on Liquidation and Cancellation of Holding Subsidiary
October 24, 2025
Announcement on Progress in Public Listing for Sale of Idle Properties
September 29, 2025
Announcement on Implementation Result of Shares Repurchase and Share Changes
September 23, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors in Chongqing Jurisdiction
September 18, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trial of Semaglutide Injection
September 9, 2025
Announcement on Unfreezing of Partial Bank Accounts of the Company and Subsidiaries
September 4, 2025
Announcement on Initially Repurchasing Shares and Progress in the Repurchase
September 3, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 21, 2025
Announcement on Sale of Idle Assets
August 14, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
August 6, 2025
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders without Sales Limits Concerning Shares Repurchase
August 1, 2025
Scheme for Repurchasing Shares through Call Auction
July 16, 2025
Announcement on Expected Decrease in Semi-annual Performance for 2025
July 14, 2025
Announcement on Cancellation of Indirect Holding Subsidiary
July 8, 2025
Announcement on Obtaining Government Subsidies
June 17, 2025
Announcement on Retirement of Senior Management Member
June 10, 2025
Announcement on Resignation of Director
June 4, 2025
Announcement on Resignation of Supervisor
May 27, 2025